论文部分内容阅读
目的:通过检测Btk及NFκB在急性淋巴细胞白血病(ALL)患者白血病细胞中的表达,评价其表达水平变化在ALL发生、发展、疾病转归及疗效判断中的意义。方法:采用Ficoll密度梯度离心法分离不同病期的51例ALL患者骨髓单个核细胞标本,利用Western blot从蛋白质水平检测Btk、NFκB的表达。结果:Btk和NFκB蛋白在51例初发ALL患者细胞中均有表达,其中38例中Btk表达水平较高,34例中NFκB表达水平较高,达完全缓解后,表达下降或检测不到(P<0.05),而同一患者复发后的白血病细胞中Btk、NFκB表达复又增高。Btk、NFκB的表达水平与ALL的治疗转归的分析显示,Btk表达增高的38例患者中27例(71%)达完全缓解,其中12例达1疗程缓解(31%),16例患者短期内复发(59%);13例Btk表达较低患者中11例达1疗程缓解(84.6%)、1例复发(7.6%);NFκB的结果与Btk类似。结论:Btk、NFκB在ALL的发生、发展及疾病转归中可能起重要作用,有可能作为ALL的潜在治疗靶点和用于预后预测。
OBJECTIVE: To evaluate the expression of Btk and NFκB in leukemia cells of patients with acute lymphoblastic leukemia (ALL) and to evaluate the significance of the changes in the expression of ALL, development, disease outcome and therapeutic efficacy. Methods: Bone marrow mononuclear cells from 51 patients with ALL at different stages were isolated by Ficoll density gradient centrifugation. The expression of Btk and NFκB was detected by Western blot. Results: Btk and NFκB were all expressed in 51 cases of ALL patients. The expression of Btk was higher in 38 cases and higher in NFκB in 34 cases. After complete remission, the expression of Btk was decreased or undetectable P <0.05). However, the expression of Btk and NFκB in leukemia cells of the same patient relapsed and increased. Analysis of Btk, NFκB expression levels and treatment outcome of ALL showed complete remission in 27 (71%) of 38 patients with elevated Btk expression, of whom 12 achieved remission in 1 course (31%) and 16 patients in short term (59%). Of the 13 patients with low Btk expression, 11 achieved remission (84.6%) in 11 patients and 1 (7.6%) relapsed. The results of NFκB were similar to those of Btk. Conclusion: Btk and NFκB may play an important role in the occurrence, development and prognosis of ALL, which may serve as a potential therapeutic target for ALL and prognosis prognosis.